A Step Ahead Towards
Better Health
  Support
Login
Newsletter
Subscription
SEDONASE 1,500,000 OR 750.000 (Vial)    

Composition:Sedonase Injection
Sedonase injection contains a highly purified streptokinase derived from cultural filtrate of beta-hemolytic streptococci of lance field group C.
The drug is supplied as a sterile, lyophilized white powder
Each vial contains: streptokinase BP 1,500,000 or 750.000 I.U.

Properties:
Acute myocardial infarction.
Deep vein thrombosis
Pulmonary embolism
Acute or sub-acute thrombosis of peripheral arteries
Chronic occlusive arterial disease
Occlusion of central retina artery or vein.

Indications:
Acute myocardial infarction:
    (IV administration) in acute myocardial infarction 1.5 million I.U of streptokinase are infused in 60 min. with this regimen
    usually no coagulation tests are necessary to monitor streptokinase therapy.
    Treatment should be started as soon as possible after the onset of symptoms.
    Significant reduction in mortality has been observed with the administration of streptokinase up to 24 hrs after onset of
    symptoms.
    However the earlier the treatment is started the greater the clinical benefit will be in terms of mortality reduction.
Intracoronary administration:
    A loading dose of 20,000 I.U, streptokinase is given as a bolus, followed by a 30 – 90 min infusion of 2000-4000 IU/min.
Deep vein thrombosis, pulmonary embolism and other indications:
    Streptokinase treatment should be instituted as soon as possible after the thrombotic event. Streptokinase therapy is unlikely
    to be beneficial if instituted
In more than 14 days after the onset of deep venous thrombosis
6 -8 hours after onset of central retinal artery occlusion.
10 days from onset of central retinal vein thrombosis
6 weeks in chronic arterial occlusions
An initial dose of 250,000 I.U streptokinase, by intravenous infusion over a period of 30 min is given. Followed by a
    maintenance dose of 100,000 I.U per hour for 24 to 72 hrs, depending on the response.
Heparin should not be reinstituted during or following streptokinase infusion until the TT or APTT have reached less than
    twice or 1.5 times the normal control value respectively.

Warning:
Vials each containing 1,500,000 or 750.000 IU

Facts About Streptokinase

  Home Online Order Useful Links Site Map Privacy Policy  
© 2004 SEDICO Co. All rights reserved
Designed & Developed by EBM Co.